Genpact's stock price experienced a significant decline of 8.72% during intraday trading on Friday, reflecting a sharp sell-off in the company's shares.

The price drop appears to be driven by negative analyst sentiment, with at least two major financial institutions reducing their price targets for the company. JP Morgan cut its target price for Genpact to $40 from $50, representing a substantial 20% reduction. Additionally, BMO lowered its target price to $39 from $44, indicating reduced confidence in the company's near-term prospects.

These analyst downgrades typically signal concerns about a company's future performance and can trigger selling pressure as investors reassess their positions based on the revised outlook from financial institutions.